Sign In
19 Sep 2016 11:14
For immediate release | 19 September 2016 |
ANGLE plc
("ANGLE" or "the Company")
Issue of Equity
ANGLE plc (AIM:AGL and OTCQX:ANPCY), the specialist medtech company, announces that it has received notice from an employee to exercise options over 22,000 ordinary shares of 10p each in the Company. Share options were issued to employees pursuant to the arrangements set out in the Company's Share Option Schemes.
Accordingly the Company has issued and allotted 22,000 new ordinary shares of 10p each ("New Ordinary Shares") in the capital of the Company. The New Ordinary Shares rank pari passu with the existing ordinary shares in the Company. An application has been made for the New Ordinary Shares to be admitted to trading on AIM and admission is expected to take place at 8.00 am on 23 September 2016. Following this allotment, the total issued share capital of the Company is 74,815,774 ordinary shares.
For further information:
ANGLE plc | 01483 685830 |
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
| |
Cenkos Securities Stephen Keys (Nominated adviser) Russell Kerr, Olly Baxendale (Sales)
| 020 7397 8900 |
WG Partners David Wilson Claes Spång
| 020 3705 9330 |
FTI Consulting Simon Conway, Mo Noonan, Stephanie Cuthbert Kimberley Ha (US) |
020 3727 1000 001 212 850 5612 |
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a specialist medtech company commercialising a disruptive platform technology that can capture cells circulating in blood, such as cancer cells, even when they are as rare in number as one cell in one billion blood cells, and harvest the cells for analysis.
ANGLE's cell separation technology is called the ParsortixTM system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix is the subject of granted patents in Europe, the United States, Canada, China and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures live cells based on a combination of their size and compressibility. Parsortix has a CE Mark for Europe and FDA authorisation is in process for the United States.
ANGLE has established formal collaborations with world-class cancer centres. These Key Opinion Leaders are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. Details are available here http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient blood with ANGLE's Parsortix system has the potential to help deliver personalised cancer care offering profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is set to drive a multi-billion dollar clinical market. The Parsortix system is designed to be compatible with existing major medtech analytical platforms and to act as a companion diagnostic for major pharma in helping to identify patients that will benefit from a particular drug and then monitoring the drug's effectiveness.
As well as cancer, the Parsortix technology has the potential for deployment with several other important cell types in the future.
ANGLE stock trades on the AIM market of the London Stock Exchange under the ticker symbol AGL and in New York on the OTC-QX under the ticker symbol ANPCY. For further information please visit: www.angleplc.com
Follow the stocks
